Success Metrics

Clinical Success Rate
66.7%

Based on 12 completed trials

Completion Rate
67%(12/18)
Active Trials
8(26%)
Results Posted
83%(10 trials)
Terminated
6(19%)

Phase Distribution

Ph phase_1
9
29%
Ph phase_3
2
6%
Ph early_phase_1
3
10%
Ph phase_2
17
55%

Phase Distribution

12

Early Stage

17

Mid Stage

2

Late Stage

Phase Distribution31 total trials
Early Phase 1First-in-human
3(9.7%)
Phase 1Safety & dosage
9(29.0%)
Phase 2Efficacy & side effects
17(54.8%)
Phase 3Large-scale testing
2(6.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

12 of 20 finished

Non-Completion Rate

40.0%

8 ended early

Currently Active

8

trials recruiting

Total Trials

31

all time

Status Distribution
Active(9)
Completed(12)
Terminated(8)
Other(2)

Detailed Status

Completed12
Terminated6
Recruiting6
Active, not recruiting2
unknown2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
31
Active
8
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Early Phase 13 (9.7%)
Phase 19 (29.0%)
Phase 217 (54.8%)
Phase 32 (6.5%)

Trials by Status

active_not_recruiting26%
completed1239%
terminated619%
unknown26%
not_yet_recruiting13%
recruiting619%
withdrawn26%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT07570173Phase 2

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

Not Yet Recruiting
NCT06679829Phase 2

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Recruiting
NCT05684692Phase 2

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Recruiting
NCT05316116Early Phase 1

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Terminated
NCT06470971Phase 2

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Recruiting
NCT06990711Phase 1

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation

Recruiting
NCT03315026Phase 2

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Active Not Recruiting
NCT04975555Phase 2

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Active Not Recruiting
NCT04191421Phase 1

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Completed
NCT07106671Phase 2

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Recruiting
NCT06447376Phase 1

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Recruiting
NCT06352866Phase 2

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Withdrawn
NCT05665725Phase 1

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

Completed
NCT04329650Phase 2

Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia

Completed
NCT02796859Phase 1

Siltuximab in Schizophrenia

Unknown
NCT05697510Phase 1

Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM

Unknown
NCT04330638Phase 3

Treatment of COVID-19 Patients With Anti-interleukin Drugs

Completed
NCT04616586Phase 3

SILtuximab in Viral ARds (SILVAR) Study

Terminated
NCT04838860Phase 2

Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

Terminated
NCT01484275Phase 2

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Completed

Drug Details

Intervention Type
DRUG
Total Trials
31